QUICK ANSWER · AEO / GEO
An experimental tetrapeptide with limited human evidence; cell or biomarker findings do not establish human lifespan extension.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- whether human-study material was free base, acetate or another formulation
- whether biomarker changes produce better sleep or any patient-important outcome
- efficacy and safety in people with diagnosed insomnia
- effects on human lifespan, healthspan, cancer risk and long-term organ function
- human pharmacokinetics, dose-response and route comparability
- independent replication beyond a concentrated research network
- current Thailand and Russia regulatory status pending direct official verification
What limits these conclusions?
- The available human evidence is biomarker-focused, short-term and does not evaluate insomnia or longevity outcomes. Much of the broader literature comes from related investigators and mixes Epitalon with Epithalamin, a different pineal extract. Cell, mouse and primate findings cannot be merged into a human efficacy claim. FDA found no clinical safety studies and no evidence supporting insomnia treatment.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://www.fda.gov/media/193345/download
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://pubmed.ncbi.nlm.nih.gov/33280326/
- https://pubmed.ncbi.nlm.nih.gov/12937682/
- https://pubmed.ncbi.nlm.nih.gov/14501183/
- https://pubmed.ncbi.nlm.nih.gov/29124531/
- https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list
- https://products.mhra.gov.uk/
FAQ · ANSWER ENGINE
Frequently asked questions
What is Epitalon?
Epitalon is described pharmacologically as Experimental synthetic pineal-derived tetrapeptide. An experimental tetrapeptide with limited human evidence; cell or biomarker findings do not establish human lifespan extension.
Does Epitalon have strong evidence?
PrimeCoreBio records Evidence Grade C. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Epitalon approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.